- $82.42m
- -$42.54m
- 24
- 49
- 52
- 35
Annual balance sheet for Adicet Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 94.6 | 278 | 258 | 160 | 176 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 2.73 | 0.214 | 0.435 | 0 | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 100 | 282 | 261 | 162 | 180 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 25.9 | 35 | 49 | 44.2 | 36.8 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 154 | 339 | 331 | 207 | 220 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 22.5 | 16.3 | 19.7 | 19.3 | 19.4 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 44 | 35.8 | 38.4 | 37.1 | 33.6 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 110 | 303 | 292 | 170 | 187 |
| Total Liabilities & Shareholders' Equity | 154 | 339 | 331 | 207 | 220 |
| Total Common Shares Outstanding |